Market Summary

Introduction

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Polycystic Kidney Disease Drugs Market Overview: 8 Major Markets

    3.1    Polycystic Kidney Disease Drugs Market Historical Value (2017-2023) 
    3.2    Polycystic Kidney Disease Drugs Market Forecast Value (2024-2032)
4    Polycystic Kidney Disease Overview 
    4.1    Guidelines and Stages
    4.2    Pathophysiology
    4.3    Screening and Diagnosis
    4.4    Therapy Pathway 
5    Patient  Profile
    5.1    Patient Profile Overview
    5.2    Patient Psychology and Emotional Impact Factors
    5.3    Risk Assessment and Therapy Success Rate
6    Polycystic Kidney Disease Epidemiology Scenario and Forecast – 8 Major Markets
    6.1    8MM Epidemiology Scenario Overview (2017-2032)
    6.2    United States Polycystic Kidney Disease Epidemiology Scenario and Forecast (2017-2032)
    6.3    EU-4 and United Kingdom Polycystic Kidney Disease Epidemiology Scenario and Forecast (2017-2032)
        6.3.1    Germany Polycystic Kidney Disease Epidemiology Scenario and Forecast (2017-2032)
            6.3.1.1    France Polycystic Kidney Disease Epidemiology Scenario and Forecast (2017-2032)
            6.3.1.2    Italy Polycystic Kidney Disease Epidemiology Scenario and Forecast (2017-2032)
            6.3.1.3    Spain Polycystic Kidney Disease Epidemiology Scenario and Forecast (2017-2032)
            6.3.1.4    United Kingdom Polycystic Kidney Disease Epidemiology Scenario and Forecast (2017-2032)
    6.4    Japan Polycystic Kidney Disease Epidemiology Scenario and Forecast (2017-2032) 
    6.5    India Polycystic Kidney Disease Epidemiology Scenario and Forecast (2017-2032)
7    Polycystic Kidney Disease Drugs Market Landscape: 8 Major Markets*
    7.1    Polycystic Kidney Disease Drugs: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Polycystic Kidney Disease Drugs: Product Landscape 
        7.2.1    Analysis by Indication
        7.2.2    Analysis by Drug Class
        7.2.3    Analysis by Route of Administration 
8    Polycystic Kidney Disease Therapy Challenges and Unmet Needs
    8.1    Therapy Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Polycystic Kidney Disease Drugs Market Dynamics
    9.1    Market Drivers and Constraints
    9.2    SWOT Analysis
        9.2.1    Strengths
        9.2.2    Weaknesses
        9.2.3    Opportunities
        9.2.4    Threats
    9.3    Porter’s Five Forces Model
        9.3.1    Bargaining Power of Suppliers
        9.3.2    Bargaining Power of Buyers
        9.3.3    Threat of New Entrants
        9.3.4    Threat of Substitutes
        9.3.5    Degree of Rivalry
    9.4    Key Demand Indicators 
    9.5    Key Price Indicators
    9.6    Industry Events, Initiatives, and Trends 
    9.7    Value Chain Analysis
10    Polycystic Kidney Disease Drugs Market Segmentation: 8 Major Markets
    10.1    Polycystic Kidney Disease Drugs Market by Disease Type
        10.1.1    Market Overview
        10.1.2    Autosomal Dominant Polycystic Kidney Disease
        10.1.3    Autosomal Recessive Polycystic Kidney Disease
    10.2    Polycystic Kidney Disease Drugs Market by Route of Administration
        10.2.1    Market Overview
        10.2.2    Oral    
        10.2.3    Parenteral
        10.2.4    Others
    10.3    Polycystic Kidney Disease Drugs Market by Distribution Channel
        10.3.1    Market Overview
        10.3.2    Hospital Pharmacies
        10.3.3    Retail Pharmacies
        10.3.4    Others
    10.4    Polycystic Kidney Disease Drugs Market by Region
        10.4.1    Market Overview
        10.4.2    United States
        10.4.3    EU-4 and the United Kingdom
            10.4.3.1    Germany
            10.4.3.2    France
            10.4.3.3    Italy
            10.4.3.4    Spain
            10.4.3.5    United Kingdom
        10.4.4    Japan
        10.4.5    India
11    United States Polycystic Kidney Disease Drugs Market (2017-2032)
    11.1    United States Polycystic Kidney Disease Drugs Market Historical Value (2017-2023) 
    11.2    United States Polycystic Kidney Disease Drugs Market Forecast Value (2024-2032)
    11.3    United States Polycystic Kidney Disease Drugs Market (2017-2032) by Disease Type
        11.3.1    Market Overview
        11.3.2    Autosomal Dominant Polycystic Kidney Disease
        11.3.3    Autosomal Recessive Polycystic Kidney Disease
    11.4    United States Polycystic Kidney Disease Drugs Market (2017-2032) by Route of Administration
        11.4.1    Market Overview
        11.4.2    Oral
        11.4.3    Parenteral
        11.4.4    Others
12    EU-4 and United Kingdom Polycystic Kidney Disease Drugs Market (2017-2032)
    12.1    EU-4 and United Kingdom Polycystic Kidney Disease Drugs Market Historical Value (2017-2023)
    12.2    EU-4 and United Kingdom Polycystic Kidney Disease Drugs Market Forecast Value (2024-2032)
    12.3    EU-4 and United Kingdom Polycystic Kidney Disease Drugs Market (2017-2032) by Disease Type
        12.3.1    Market Overview
        12.3.2    Autosomal Dominant Polycystic Kidney Disease
        12.3.3    Autosomal Recessive Polycystic Kidney Disease
    12.4    EU-4 and United Kingdom Polycystic Kidney Disease Drugs Market (2017-2032) by Route of Administration
        12.4.1    Market Overview
        12.4.2    Oral
        12.4.3    Parenteral
        12.4.4    Others
13    Japan Polycystic Kidney Disease Drugs Market 
    13.1    Japan Polycystic Kidney Disease Drugs Market Historical Value (2017-2023) 
    13.2    Japan Polycystic Kidney Disease Drugs Market Forecast Value (2024-2032)
    13.3    Japan Polycystic Kidney Disease Drugs Market (2017-2032) by Disease Type
        13.3.1    Market Overview
        13.3.2    Autosomal Dominant Polycystic Kidney Disease
        13.3.3    Autosomal Recessive Polycystic Kidney Disease
    13.4    Japan Polycystic Kidney Disease Drugs Market (2017-2032) by Route of Administration
        13.4.1    Market Overview
        13.4.2    Oral
        13.4.3    Parenteral
        13.4.4    Others
14    India Polycystic Kidney Disease Drugs Market
    14.1    India Polycystic Kidney Disease Drugs Market (2017-2032) Historical Value (2017-2023) 
    14.2    India Polycystic Kidney Disease Drugs Market (2017-2032) Forecast Value (2024-2032)
    14.3    India Polycystic Kidney Disease Drugs Market (2017-2032) by Disease Type
        14.3.1    Market Overview
        14.3.2    Autosomal Dominant Polycystic Kidney Disease
        14.3.3    Autosomal Recessive Polycystic Kidney Disease
    14.4    India Polycystic Kidney Disease Drugs Market (2017-2032) by Route of Administration
        14.4.1    Market Overview
        14.4.2    Oral
        14.4.3    Parenteral
        14.4.4    Others
15    Regulatory Framework
    15.1    Regulatory Overview
    15.2    US FDA
    15.3    EU EMA
    15.4    INDIA CDSCO
    15.5    JAPAN PMDA
    15.6    Others
16    Patent Analysis
    16.1     Analysis by Type of Patent
    16.2     Analysis by Publication Year
    16.3     Analysis by Issuing Authority
    16.4     Analysis by Patent Age
    16.5     Analysis by CPC Analysis
    16.6     Analysis by Patent Valuation 
    16.7     Analysis by Key Players
17    Clinical Trial Analysis
    17.1    Analysis by Trial Registration Year
    17.2    Analysis by Trial Status
    17.3    Analysis by Trial Phase
    17.4    Analysis by Therapeutic Area
    17.5    Analysis by Geography
18    Grant Analysis
    18.1    Analysis by Year
    18.2    Analysis by Amount Awarded
    18.3    Analysis by Issuing Authority
    18.4    Analysis by Grant Product
    18.5    Analysis by Funding Institute
    18.6    Analysis by Departments
    18.7    Analysis by Recipient Organization
19    Funding and Investment Analysis
    19.1     Analysis by Funding Instances
    19.2     Analysis by Type of Funding
    19.3     Analysis by Funding Amount
    19.4     Analysis by Leading Players
    19.5     Analysis by Leading Investors
    19.6     Analysis by Geography
20    Partnership and Collaborations Analysis
    20.1     Analysis by Partnership Instances
    20.2     Analysis by Type of Partnership
    20.3     Analysis by Leading Players
    20.4     Analysis by Geography
21    Supplier Landscape
    21.1     Market Share by Top 5 Companies
    21.2     AbbVie Inc.
        21.2.1    Financial Analysis
        21.2.2    Product Portfolio
        21.2.3    Demographic Reach and Achievements
        21.2.4    Mergers and Acquisitions
        21.2.5    Certifications 
    21.3    Apotex Inc.
        21.3.1    Financial Analysis
        21.3.2    Product Portfolio
        21.3.3    Demographic Reach and Achievements
        21.3.4    Mergers and Acquisitions
        21.3.5    Certifications
    21.4    Amgen Inc.
        21.4.1    Financial Analysis
        21.4.2    Product Portfolio
        21.4.3    Demographic Reach and Achievements
        21.4.4    Mergers and Acquisitions
        21.4.5    Certifications
    21.5    F. Hoffmann-La Roche Ltd.
        21.5.1    Financial Analysis
        21.5.2    Product Portfolio
        21.5.3    Demographic Reach and Achievements
        21.5.4    Mergers and Acquisitions
        21.5.5    Certifications
    21.6    Galapagos NV
        21.6.1    Financial Analysis
        21.6.2    Product Portfolio
        21.6.3    Demographic Reach and Achievements
        21.6.4    Mergers and Acquisitions
        21.6.5    Certifications
    21.7    Johnson & Johnson Services, Inc.
        21.7.1    Financial Analysis
        21.7.2    Product Portfolio
        21.7.3    Demographic Reach and Achievements
        21.7.4    Mergers and Acquisitions
        21.7.5    Certifications
    21.8    Merck and Co. Inc.
        21.8.1    Financial Analysis
        21.8.2    Product Portfolio
        21.8.3    Demographic Reach and Achievements
        21.8.4    Mergers and Acquisitions
        21.8.5    Certifications
    21.9    Otsuka Holdings Co. Ltd
        21.9.1    Financial Analysis
        21.9.2    Product Portfolio
        21.9.3    Demographic Reach and Achievements
        21.9.4    Mergers and Acquisitions
        21.9.5    Certifications 
    21.10    Palladio Biosciences Inc.
        21.10.1    Financial Analysis
        21.10.2    Product Portfolio
        21.10.3    Demographic Reach and Achievements
        21.10.4    Mergers and Acquisitions
        21.10.5    Certifications 
    21.11    Regulus Therapeutics 
        21.11.1    Financial Analysis
        21.11.2    Product Portfolio
        21.11.3    Demographic Reach and Achievements
        21.11.4    Mergers and Acquisitions
        21.11.5    Certifications
    21.12    Sanofi SA
        21.12.1    Financial Analysis
        21.12.2    Product Portfolio
        21.12.3    Demographic
        21.12.4    Mergers and Acquisitions
        21.12.5    Certifications
    21.13    XORTX Therapeutics Inc
        21.13.1    Financial Analysis
        21.13.2    Product Portfolio
        21.13.3    Demographic Reach and Achievements
        21.13.4    Mergers and Acquisitions
        21.13.5    Certifications
    21.14    Novartis AG
        21.14.1    Financial Analysis
        21.14.2    Product Portfolio
        21.14.3    Demographic Reach and Achievements
        21.14.4    Mergers and Acquisitions
        21.14.5    Certifications
    21.15    Teva Pharmaceutical Industries Ltd.
        21.15.1    Financial Analysis
        21.15.2    Product Portfolio
        21.15.3    Demographic Reach and Achievements
        21.15.4    Mergers and Acquisitions
        21.15.5    Certifications 
    21.16    Bayer AG
        21.16.1    Financial Analysis
        21.16.2    Product Portfolio
        21.16.3    Demographic Reach and Achievements
        21.16.4    Mergers and Acquisitions
        21.16.5    Certifications 
22    Polycystic Kidney Disease Drugs Market – Distribution Model (Additional Insight)
    22.1     Overview 
    22.2     Potential Distributors 
    22.3     Key Parameters for Distribution Partner Assessment 
23    Key Opinion Leaders (KOL) Insights (Additional Insight)
24    Company  Competitiveness Analysis (Additional Insight)

    24.1     Very Small Companies
    24.2     Small Companies
    24.3     Mid-Sized Companies
    24.4     Large Companies
    24.5     Very Large Companies
25    Payment Methods (Additional Insight)
    25.1    Government Funded
    25.2    Private Insurance
    25.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

 

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

*Additional insights provided are customizable as per client requirements.

*The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

*The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.

Looking for specific insights?

Get in touch with us today for customized, data-driven solutions tailored to your unique requirements!

Purchase Full Report

Datasheet

 

USD 2,969

USD 2,699

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 5,499

USD 4,999

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 6,599

USD 5,999

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 7,699

USD 6,999

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

Back to top

We’re here to help answer any questions about our products and services.

Contact us

Locations


United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Australia

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63 287899028, +63 967 048 3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124